You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Transform lives with Nucala by exacerbation reduction

Nucala could allow patients with severe asthma to get their lives back
through protection that lasts.
1-4

Help for patients

Useful tips for your adult patients who are receiving Nucala treatment.

Discover more>

References:

  1. Ortega HG et al. N Engl J Med 2014; 371:1198–1207.
  2. Chupp GL et al. Lancet Respir Med 2017; 5:390–400.
  3. Ortega HG et al. Lancet Respir Med 2016; 4:549–556.
  4. Khatri et al. Available at https://doi.org/10.1016/j.jaci.2018.09.033. Accessed January 2019.
  5. Nucala SmPC 2019. Available at www.medicines.ie Last accessed January 2019.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Copyright © 2019 GlaxoSmithKline Group of Companies. All rights reserved.
Nucala is a registered trademark of the GlaxoSmithKline Group of Companies.